… Author links open overlay panel David Montani a b c , Marie-Camille Chaumais c d e ,
Christophe Guignabert a b c , Sven Günther a b c , Barbara Girerd a b c , Xavier Jaïs a b c , …

Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pulmonary hypertension
(PH) characterized by progressive obstruction of small pulmonary veins and a dismal …

Pulmonary arterial hypertension (PAH) is a rare disease characterized by vascular proliferation
and remodeling, resulting in a progressive increase in pulmonary arterial resistance, …

Background Viral respiratory infections are the main causes of asthma exacerbation. The
susceptibility of patients with asthma to develop an exacerbation when they present with …

Background— Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pulmonary
hypertension characterized by the obstruction of small pulmonary veins and a dismal …

This study aimed to describe the long-term outcomes of pulmonary arterial hypertension (PAH)
induced by dasatinib. 21 incident, right heart catheterisation-confirmed cases of dasatinib-…

Idiopathic nephrotic syndrome is the most frequent glomerular disease during childhood.
Although immunosuppressive agents are usually effective, some severe cases remain difficult …

Isolated cases of pulmonary arterial hypertension (PAH) in patients treated with interferon (IFN)
α or β have been reported in the literature. The aim of this study was to describe all …

Benfluorex was marketed in France until 2009, despite its similar pharmacological
properties with fenfluramine and its derivatives known to be a cause of pulmonary arterial …

Sofosbuvir and daclatasvir are direct-acting antiviral drugs used to treat chronic hepatitis C
virus infection. In 2015, the Food and Drug Administration and European Medical Agency …